MX9601149A - Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista. - Google Patents

Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista.

Info

Publication number
MX9601149A
MX9601149A MX9601149A MX9601149A MX9601149A MX 9601149 A MX9601149 A MX 9601149A MX 9601149 A MX9601149 A MX 9601149A MX 9601149 A MX9601149 A MX 9601149A MX 9601149 A MX9601149 A MX 9601149A
Authority
MX
Mexico
Prior art keywords
antagonist
palpebral
ocular
dysaesthesias
pruritus
Prior art date
Application number
MX9601149A
Other languages
English (en)
Other versions
MXPA96001149A (es
Inventor
Olivier De Lacharriere
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Publication of MXPA96001149A publication Critical patent/MXPA96001149A/es
Publication of MX9601149A publication Critical patent/MX9601149A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invencion se refiere al uso de un antagonista del CGRP (péptido derivado del gen de calcitonina) en, o para la preparacion de una composicion cosmética o farmacéutica, en particular uno para la aplicacion topica, para tratar prurito ocular o palpebral, dolor ocular o palpebral y disestesia oculares o palpebrales. La composicion cosmética se puede usar para aplicar maquillaje a, o remover el maquillaje de los ojos sensibles.
MX9601149A 1995-03-28 1996-03-27 Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista. MX9601149A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9503629A FR2732222B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR95-03629 1995-03-28
FR9503629 1995-03-28

Publications (2)

Publication Number Publication Date
MXPA96001149A MXPA96001149A (es) 1997-08-01
MX9601149A true MX9601149A (es) 1997-08-30

Family

ID=9477499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9601149A MX9601149A (es) 1995-03-28 1996-03-27 Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista.

Country Status (15)

Country Link
US (2) US6169069B1 (es)
EP (1) EP0734730B1 (es)
JP (1) JP3024064B2 (es)
AR (1) AR002975A1 (es)
AT (1) ATE205089T1 (es)
BR (1) BR9601461A (es)
CA (1) CA2172779C (es)
DE (1) DE69614907T2 (es)
DK (1) DK0734730T3 (es)
ES (1) ES2163596T3 (es)
FR (1) FR2732222B1 (es)
HU (1) HUP9600766A3 (es)
MX (1) MX9601149A (es)
PL (1) PL313513A1 (es)
RU (1) RU2155601C2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7112334B2 (en) * 2001-06-05 2006-09-26 Freiberg Roberta C Allergy inhibition
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
PE20141031A1 (es) * 2011-06-28 2014-08-21 Bayer Healthcare Llc Composicion farmaceutica oftalmologica topica que contiene regorafenib
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20190066607A (ko) 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye

Also Published As

Publication number Publication date
DE69614907D1 (de) 2001-10-11
ATE205089T1 (de) 2001-09-15
ES2163596T3 (es) 2002-02-01
US6344438B1 (en) 2002-02-05
EP0734730A1 (fr) 1996-10-02
JP3024064B2 (ja) 2000-03-21
DE69614907T2 (de) 2002-01-17
PL313513A1 (en) 1996-09-30
JPH08268913A (ja) 1996-10-15
HUP9600766A3 (en) 1998-04-28
US6169069B1 (en) 2001-01-02
BR9601461A (pt) 1998-03-31
HU9600766D0 (en) 1996-05-28
RU2155601C2 (ru) 2000-09-10
EP0734730B1 (fr) 2001-09-05
HUP9600766A2 (en) 1997-06-30
AR002975A1 (es) 1998-05-27
CA2172779A1 (fr) 1996-09-29
FR2732222A1 (fr) 1996-10-04
DK0734730T3 (da) 2001-12-17
CA2172779C (fr) 2001-12-25
FR2732222B1 (fr) 1997-04-25

Similar Documents

Publication Publication Date Title
MX9601149A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista.
HUP9600162A3 (en) Use of an antagonist of cgrp in cosmetic, pharmaceutical or dermatological compositions and the cosmetic compositions
MX9803492A (es) Composicion limpiadora personal.
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
GB9317104D0 (en) Therapeutic heterocycles
FR2779647B1 (fr) Composition cosmetique contenant un polymere anionique et un terpolymere acrylique et utilisation de cette composition pour le traitement des matieres keratiniques
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
HK1020867A1 (en) The topical use of kappa opioid agonists to treat ocular pain k
GEP20063844B (en) Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
WO1999009964A3 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektion
AU682166B2 (en) Synergising association having an antagonist effect on NK1 and NK2 receptors
PL312908A1 (en) Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors
MX9601151A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento de liquenes y prurito y composicion obtenida.
MX9505180A (es) Uso de un antagonista de la substancia p para la obtencion de una composicion farmaceutica para el tratamiento de prurito y disestesias oculares o palpebrales.
DK0840607T3 (da) Ny medicinsk anvendelse
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
PT862462E (pt) Uma nova combinacao de um bloqueador de receptores beta e de um opioide
AU5816396A (en) Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction
AU1294195A (en) Compositions and methods for the treatment of dry eyes and other ocular disorders
AU4123297A (en) Alkaloid glycoside for use as a medicament
MX9801156A (es) Sistema de limpieza personal que comprende una esponja de baño de malla de diamante polimerica y un limpiador liquido con biocida halogenado.
IL116548A0 (en) Pharmaceutical compositions for treatment of the eyes

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees